Outcomes in randomized clinical trials of metastatic pancreatic cancer (first-line treatment)
| Chemotherapy | Phase | Number of patients | mOS | mPFS | ORR | Ref. |
|---|---|---|---|---|---|---|
| Gemcitabine vs. 5-fluorouracile | II/III | 126 | 5.56 months vs. 4.41 months (P = 0.0025) | 2.33 months vs. 0.92 months (P = 0.0002) | 5.4% vs. 0% (nc) | [5] |
| Gemcitabine plus erlotinib vs. gemcitabine | III | 569 | 6.24 months vs. 5.91 months (P = 0.038, HR: 0.82) | 3.75 months vs. 3.55 months (P = 0.004, HR: 0.77) | 8.6% vs. 8% (nc) | [6] |
| FOLFIRINOX vs. gemcitabine | II/III | 342 | 11.1 months vs. 6.8 months (P < 0.001, HR: 0.57) | 6.4 months vs. 3.3 months (P < 0.001, HR: 0.47) | 31.6% vs. 9.4% (P < 0.001) | [7] |
| Gemcitabine plus nab-paclitaxel vs. gemcitabine | III | 861 | 8.5 months vs. 6.7 months (P < 0.001, HR: 0.72) | 5.5 months vs. 3.7 months (P < 0.001, HR: 0.69) | 23% vs. 7% (P < 0.001) | [8] |
| Gemcitabine plus capecitabine vs. gemcitabine | III | 533 | 7.1 months vs. 6.2 months (P = 0.08, HR: 0.86) | 5.3 months vs. 3.8 months (P = 0.004, HR: 0.78) | 19.1% vs. 12.4% (P = 0.034) | [9] |
| NALIRIFOX vs. gemcitabine plus nab-paclitaxel | III | 770 | 11.1 months vs. 9.2 months (P = 0.036, HR: 0.83) | 7.4 months vs. 5.6 months (P < 0.0001, HR: 0.69) | 42% vs. 36% (P = 0.11) | [10] |
mOS: median overall survival; mPFS: median progression-free survival; ORR: objective response rate; Ref.: references; nc: not calculated; HR: hazard ratio